MariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel Chews
NORWOOD, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- ™, the all-natural cannabis chews handcrafted to fit a variety of needs, is expanding its lineup with the introduction of delicious caramel chews: Betty's Caramelt Away. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. ('MariMed') (CSE: MRMD) (OTCQX: MRMD).
Debuting in time for National Caramel Day on April 5, Betty's Caramelt Away chews are now available at select cannabis retailers throughout Massachusetts, with plans for expansion into MariMed's wholesale markets in the future. Each chew wraps customers in warmth with the rich, comforting flavor of classic caramel. They're infused with a soothing blend of full-spectrum hash and CBG that lets consumers sink into sweet, cozy melty moments of mellow.
'Betty's Eddies and caramel is the perfect pairing of two fan favorites,' said Sara Rosenfield, Brand Director at MariMed for Betty's Eddies. Betty's Eddies is the most popular edible brand in several of our core markets: Massachusetts, Maryland, and Delaware. Caramel consistently ranks among the most popular ingredients in candy and other sweet treats. Cannabis consumers will love the full-flavor, full-spectrum experience that the brand is known for with the creamy deliciousness of caramel.'
Betty's Caramelt Away joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Smashin' Passion for sexual wellness, and Betty Good Times for any time.
About Betty's EddiesBetty's Eddies™ all-natural fruit chews are handcrafted with full-spectrum cannabis, supporting cannabinoids, and herbal supplements and vitamins. Designed for whatever life throws at you, varieties include pain relief, immunity, energy, sleep and more. Founded in 2014 by medical cannabis patients on a mission to craft the best tasting and most effective edibles, best-selling Betty's Eddies encompass the full spectrum of the plant's benefits, including natural adaptogens, and are handcrafted in small batches with real organic fruits and vegetables. Find Betty's Eddies in licensed dispensaries in Delaware, Maryland, Massachusetts, and Missouri. Learn more at www.bettyseddies.com.
About MariMedMariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby's Baked™, Vibations™, InHouse™, and Nature's Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
Media Contact:Zach GalassoDPA Communications Email: zach@dpacommunications.comPhone: (978) 604-5423
Company Contact:Howard SchacterChief Communications Officer Email: hschacter@marimedinc.comPhone: (781) 277-0007
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AI-Powered Pathogen Detection App: Provisional Patent Filed by FendX CEO
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce that its CEO, Dr. Carolyn Myers, has filed a provisional patent application with the United States Patent and Trademark Office. The application, titled "AI Adaptive App Pathogen Detection Platform" dated June 25, 2025, will be assigned to FendX as part of its expanding portfolio of hygiene-related technologies. The invention described in the patent application is being designed to combine mobile-based imaging, biosensor technology, and artificial intelligence ("AI") to enable real-time detection of pathogens on surfaces using a mobile device such as a smartphone. The aim is to develop a portable, intelligent and user-friendly diagnostic tool for both consumer and professional use. "Traditional diagnostic methods are powerful but often take time to detect and identify pathogens, and they're usually limited to lab settings," said Dr. Carolyn Myers, FendX CEO and inventor. "This invention is part of our ongoing commitment to making surface protection smarter and I believe it shows how mobile devices and AI can work together to bring advanced pathogen detection directly to the user." About FendX Technologies Inc. FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing an eco-friendly, smart sponge designed to deliver effective cleaning while minimizing environmental impact. This innovative product complements FendX's broader pipeline, which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and a spray-based coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds an exclusive supply agreement for the eco-sponge and an exclusive license to certain intellectual property related to the use of the sponge, as well as exclusive worldwide licenses and intellectual property for its coating technologies. ON BEHALF OF THE COMPANY "Carolyn Myers"Carolyn MyersChief Executive Officer and Director Contacts: Dr. Carolyn Myers, CEO and Director1-800-344-9868investor@ For more information, please visit and the Company's profile on SEDAR+ at Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, invention and goals related to the development of the invention;; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development of the invention;; risks related to research and development activities for each of the film, spray formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company's products, including the eco-friendly sponge, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP, including the provisional patent application to be assigned to the Company; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei
In this episode of Health is a Skill, Rachelle Ramiro shares how catching multiple myeloma early led to deeper self-awareness—and powerful healing tools like HBOT, exosomes, and radical self-care. Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill Podcast Beverly Hills California, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On this new episode of Health is a Skill, host Todd Vande Hei welcomes Rachelle Ramiro, founder of CEO2 Health, for a revealing conversation about how a life-changing diagnosis reshaped her relationship with time, energy, and well-being. Diagnosed with multiple myeloma in her early 30s, Ramiro chose to take a proactive, multi-dimensional approach to healing. Speaking from inside a hyperbaric oxygen chamber, she details how early detection, unconventional therapies, and consistent recovery practices helped her normalize her labs, regain vitality, and stay fully engaged in both work and life. Key topics from the conversation include: Listening to your body: How Ramiro caught signs of cancer before her doctors did—beginning with elevated heart rate and night sweats. Hyperbaric oxygen therapy (HBOT): Why it became her foundation for lowering inflammation, improving sleep, and speeding recovery. Cutting-edge treatments: How exosomes, NAD+, and infrared saunas supported her immunity, cognitive clarity, and resilience. The danger of comfort: Why today's culture of ease is quietly undermining physical and mental health, and how embracing discomfort can heal. Reframing health: From cold plunges to meditation, Ramiro shares how discomfort, presence, and gratitude transformed her mindset and daily energy. Ramiro says, 'At one point, I couldn't even walk because of the pain. But after starting therapies like exosomes, I felt hopeful, mobile, and even joyful. I'm walking in Italy today because I chose to invest in my wellness.' The discussion also explores the growing role of mobile wellness: CEO2 Health now delivers hyperbaric oxygen therapy across homes, offices, events, and luxury spaces through portable chambers and custom installations. To learn more about personalized recovery and mobile hyperbaric therapy, visit About Health Is a SkillHealth is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark Health. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications: adamtorres@ Attachment Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill PodcastError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
